A growing demand for experimental peptides marketed as wellness and anti-aging solutions has sparked debate among researchers, regulators, and healthcare professionals in the United States. One peptide drawing particular attention is MOTS-c, a molecule discovered by scientists at the University of Southern California that appears to mimic exercise effects in animal studies. While some view it as a promising avenue for future therapies, its widespread unregulated use has raised safety concerns.

Pinchas Cohen, dean of the USC Leonard Davis School of Gerontology and one of the original discoverers of MOTS-c, expressed alarm over the black-market trade of the peptide. Available online despite lacking U.S. Food and Drug Administration (FDA) approval, MOTS-c is frequently labeled “for research use only” yet is injected by tens of thousands of consumers. Cohen highlighted that these products often come from unknown sources, with uncertain purity and sterility, creating potential health risks.

Over the past decade, social media and distrust of public health guidance have fueled consumer interest in experimental peptides marketed as “exercise in a bottle” or longevity boosters. Some peptides, such as insulin and GLP-1 analogs, have well-established therapeutic uses following extensive clinical testing. In contrast, MOTS-c and many others remain investigational, with most evidence confined to animal experiments or limited human studies, leaving questions about optimal dosing, long-term safety, and interactions unanswered.

Recently, an FDA advisory committee recommended allowing compounding pharmacies to produce certain peptides, including MOTS-c, BPC-157, TB-500, and others. Compounding pharmacies create customized drugs under state regulations but do not require FDA approval. Proponents argue this approach offers a regulated path to ensure product quality and involve healthcare providers in overseeing use, representing “the lesser of two evils” compared to the unchecked black market. Cohen, who testified before the committee, advocated for prescriber supervision and quality control to mitigate risks while acknowledging continued research is needed.

However, some FDA staff and independent experts remain skeptical of this pathway, citing insufficient safety data and concerns that compounding approvals could circumvent rigorous clinical trials. Paul Knoepfler, a professor of cell biology and anatomy, emphasized that while compounding could improve product purity relative to unregulated sources, it does not address potential inherent risks of the peptides themselves. Experts caution that current enthusiasm for peptides, often driven by wellness influencers and telehealth companies, may outpace scientific evidence.

Researchers continue to study MOTS-c’s biological role, which was identified within the so-called “dark genome”—regions of human DNA previously thought nonfunctional. To date, around 250 scientific papers have explored MOTS-c, demonstrating its effects on metabolism in mice, but its impact on humans remains largely unknown. Users often share anecdotal reports of improved energy and physical performance, though these personal accounts do not substitute for controlled trials.

The situation reflects a broader shift in healthcare, as consumers increasingly seek and pay for wellness interventions outside traditional medical systems. Cohen envisions a future in which MOTS-c and similar peptides might gain FDA approval after rigorous testing but acknowledges that drug development is costly and time-consuming, with many candidates failing to reach the market. In the meantime, he proposed establishing an anonymous online registry to collect real-world data on peptide use, including dosages and side effects, to inform ongoing research.

The debate over peptide regulation highlights tensions between innovation, safety, consumer demand, and the challenges of navigating emerging biomedical frontiers in an era of widespread information and product access. As peptide use grows, balancing public health safeguards with patient autonomy and scientific progress remains a complex policy and medical challenge.